Warning Letter Roundup & Recap – March 19, 2019
Executive Summary
Two makers of breast implants failed to comply with years-old FDA post-approval study orders, and TEI Biosciences Inc. – an Integra LifeSciences company – ran afoul of the US agency's Quality System Regulation in device-related warning letters released by FDA this week.
You may also be interested in...
Warning Letters And Close-Outs – May 2023
The US FDA issued one warning letter last month, and closed out warnings previously issued to Centurion Medical, Mentor Worldwide and Unimicro Medical Systems.
Breast Implant-Makers Now Required To File Individual Reports On Each Adverse Event, FDA Says
The agency is redoubling efforts to warn women about the risks of silicone and saline breast implants after feedback from a recent advisory panel meeting. On 2 May, the regulator said it is requiring manufacturers to file individual Medical Device Reports for each adverse event regarding implants – part of a bigger effort to end its Alternative Summary Reporting Program for all devices.
Speaking Of Medtech, Ep. 10: FDA’s TAP Pilot
In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?